Asiaticoside, a triterpenoid saponin from Centella asiatica, is an approved oral drug in China for wound and scar indications and shows dose-dependent inhibition of hypertrophic scar formation when given orally at 10–20 times the recommended human dose in the rabbit ear scar model. Two linked obstacles stand between it and a usable human systemic therapy: the parent glycoside has an absolute oral bioavailability below 1% in rats and is undetectable in human plasma after gram-scale extract doses, and no adequately controlled human study has established an efficacious, safe oral dosing regimen for hypertrophic scars. The open problem posed by the source study is the first of these: to raise systemic exposure of the active asiaticoside species at tolerable oral doses — by purification, structural modification, or formulation — so that the anti-scarring pharmacology demonstrated in animals becomes reachable in patients. Controlled human evidence that oral asiaticoside improves hypertrophic scars is still absent, and it remains the therapeutic end that this work serves rather than a second condition imposed on it.

Background

A hypertrophic scar (HS) is a fibro-proliferative skin disorder following deep dermal injury, characterised by excessive collagen deposition, prolonged inflammation, raised rigid scars that may itch, hurt, and contract joints; it is distinguished from a keloid, which extends beyond the original wound boundary. Existing treatments (intralesional corticosteroids, surgery, laser, radiotherapy) are only partially effective, and no validated oral systemic drug exists for scar-prone patients. Asiaticoside (AS) is a pentacyclic triterpenoid saponin — a large, sugar-bearing, poorly permeable molecule — extracted from the medicinal plant Centella asiatica (L.) Urb. Its sister glycoside is madecassoside, and its sugar-free breakdown products (aglycones) are asiatic acid and madecassic acid. Asiaticoside has been an approved oral tablet drug in China for decades for non-healing wounds, hypertrophic scars, and keloids in the active phase, at recommended adult doses of roughly 36–72 mg per day, yet clinical studies at this recommended dose failed to show convincing improvement of hypertrophic scars, which the source authors attribute to insufficient systemic drug exposure. Bioavailability here means the fraction of an orally administered dose reaching the systemic circulation unchanged (or as active metabolite). Pharmacokinetic studies quantify the problem: in rats given a standardised Centella extract, the absolute oral bioavailability of asiaticoside is below 1%, with the oral dose recovered in faeces as aglycone (triterpenic acid) metabolites after gut processing; in human Phase I trials of 2–4 g of Centella aqueous extract, the parent glycoside was undetectable in plasma while only the aglycones showed measurable profiles. Mechanistically, asiaticoside is a plausible anti-scarring agent: it suppresses the pro-fibrotic transforming growth factor-beta (TGF-β)/SMAD signalling cascade (SMAD proteins transduce TGF-β signals from receptor to nucleus; SMAD7 is the inhibitory feedback element), down-regulates collagen I/III and the pro-inflammatory cytokines interleukin-1β/6/8, and up-regulates the anti-fibrotic nuclear receptor PPAR-γ (peroxisome proliferator-activated receptor gamma). The rabbit ear scar model is the standard small-animal model in which punched full-thickness ear wounds develop hypertrophic-scar-like raised red plaques, allowing gross, histological (scar elevation index, i.e. the ratio of scar to normal-skin cross-sectional thickness, and collagen staining), and gene-expression readouts. In this model, Huang et al. (2021) showed that daily oral asiaticoside at 12 and 24 mg per kg per day — 10 and 20 times the Chinese clinical recommendation per body weight, gavaged for 60 days — significantly and dose-dependently inhibited hypertrophic scar formation with no detectable side effects. The authors concluded that efficacy emerges only when the dose is high enough to overcome the drug's low bioavailability, proposed that raising the clinically recommended dose could be a safe and straightforward approach, and explicitly called for future research on purifying or structurally modifying asiaticoside to enhance its bioavailability. Since the publication of that study, an extensive literature has developed around asiaticoside delivery (nanocrystals, liposomes, microneedles, supramolecular gels, co-crystals) and Centella pharmacokinetics, but reviews through 2026 continue to list low oral bioavailability and the absence of rigorous clinical trials as the unresolved obstacles to clinical use.

Problem Statement

Can asiaticoside be made into an effective oral systemic therapy for hypertrophic scars in humans? The question the source study leaves open is the exposure obstacle: can purification, structural modification, or an oral formulation of asiaticoside raise systemic exposure of the active asiaticoside species (parent glycoside or aglycone metabolite) from its current state — below 1% absolute bioavailability in rats, with the parent glycoside undetectable in human plasma at gram-scale extract doses — to levels that deliver anti-fibrotic exposure at practically administrable and safe doses, while retaining the compound's anti-scarring pharmacology (TGF-β/SMAD suppression, anti-inflammatory and collagen-modulating activity)? These routes are alternatives directed at the same exposure obstacle, not a prescribed sequence: the source asks for research on how to "purify or improve the structure of AS in order to enhance the bioavailability", and separately reports that, on the basis of its rabbit data, "ascending the clinically recommended dose of AS could be a safe and straightforward approach to treat HS" with the current tablet format; that dose-escalation remark is background from the source, not one of the resolution routes above, since increasing the dose of the existing tablet does not by itself improve bioavailability (exposure per unit dose).

The clinical situation is the context that makes this question matter, not an additional requirement layered onto it: no adequately controlled human study has established an oral asiaticoside dosing regimen — including, but not limited to, the 10–20× dose-escalation strategy suggested by the rabbit ear model data — that significantly improves established hypertrophic scars or prevents their formation in scar-prone patients, with acceptable safety over the months-long course scar maturation requires.

References

  1. Huang J, Zhou X, Xia L, Liu W, Guo F, Liu J, Liu W (2021). Inhibition of hypertrophic scar formation with oral asiaticoside treatment in a rabbit ear scar model. International Wound Journal 18(5):598–607. doi:10.1111/iwj.13561. https://doi.org/10.1111/iwj.13561 (source of the open question)
  2. Anukunwithaya T, Tantisira MH, Tantisira B, Khemawoot P (2017). Pharmacokinetics of a standardized extract of Centella asiatica ECa 233 in rats. Planta Medica 83(8):710–717. doi:10.1055/s-0042-122344. https://doi.org/10.1055/s-0042-122344
  3. Wang J, Ma C, Guo C, Yuan R, Zhan X (2016). CTG-loaded liposomes as an approach for improving the intestinal absorption of asiaticoside in Centella Total Glucosides. International Journal of Pharmaceutics 509(1–2):296–304. doi:10.1016/j.ijpharm.2016.05.044. https://doi.org/10.1016/j.ijpharm.2016.05.044
  4. Wright KM, Bollen M, David J, Speers AB, Brandes MS, Gray NE, Alcázar Magaña A, McClure C, Stevens JF, Maier CS, Quinn JF, Soumyanath A (2022). Pharmacokinetics and pharmacodynamics of key components of a standardized Centella asiatica product in cognitively impaired older adults: a Phase 1, double-blind, randomized clinical trial. Antioxidants 11(2):215. doi:10.3390/antiox11020215. https://doi.org/10.3390/antiox11020215
  5. Wright KM, Bollen M, David J, Mepham B, Alcázar Magaña A, McClure C, Maier CS, Quinn JF, Soumyanath A (2023). Bioanalytical method validation and application to a Phase 1, double-blind, randomized pharmacokinetic trial of a standardized Centella asiatica (L.) Urban water extract product in healthy older adults. Frontiers in Pharmacology 14:1228030. doi:10.3389/fphar.2023.1228030. https://doi.org/10.3389/fphar.2023.1228030
  6. He Z, Hu Y, Niu Z, Zhong K, Liu T, Yang M, Ji L, Hu W (2023). A review of pharmacokinetic and pharmacological properties of asiaticoside, a major active constituent of Centella asiatica (L.) Urb. Journal of Ethnopharmacology 302(Part A):115865. doi:10.1016/j.jep.2022.115865. https://doi.org/10.1016/j.jep.2022.115865
  7. Zhang Y, Liu E, Gao H, He Q, Chen A, Pang Y, Zhang X, Bai S, Zeng J, Guo J (2024). Natural products for the treatment of hypertrophic scars: preclinical and clinical studies. Heliyon 10(17):e37059. doi:10.1016/j.heliyon.2024.e37059. https://doi.org/10.1016/j.heliyon.2024.e37059
  8. Kumar M, Kumar D, Mahmood S, Singh V, Chopra S, Hilles AR, Bhatia A (2024). Nanotechnology-driven wound healing potential of asiaticoside: a comprehensive review. RSC Pharmaceutics 1(1):9–36. doi:10.1039/d3pm00024a. https://doi.org/10.1039/d3pm00024a
  9. Huang H, Shen Y, Yang X, Hou C, Ke X, Yang R (2024). Dissolvable microneedles loaded with asiaticoside nanocrystals stabilized by Panax notoginseng saponins for hypertrophic scar treatment. Journal of Drug Delivery Science and Technology 98:105854. doi:10.1016/j.jddst.2024.105854. https://doi.org/10.1016/j.jddst.2024.105854
  10. Paocharoen V (2010). The efficacy and side effects of oral Centella asiatica extract for wound healing promotion in diabetic wound patients. Journal of the Medical Association of Thailand 93(Suppl 7):S166–S170. PMID 21298840. https://pubmed.ncbi.nlm.nih.gov/21298840/
  11. Li L, Liu L, Wang T (2025). Effects of asiaticosides on scar recovery and psychological well-being in patients with scald injuries. Pharmacognosy Magazine 21(4):1480–1486. doi:10.1177/09731296241312483. https://doi.org/10.1177/09731296241312483
  12. Prananda AT, Nugraha SE, Situmorang PC, Syahputra RA (2025). Comparative effectiveness of plant-derived compounds in keloid management: a review. Frontiers in Pharmacology 16:1576851. doi:10.3389/fphar.2025.1576851. https://doi.org/10.3389/fphar.2025.1576851
  13. Borowicz KK (2026). Geroprotective potential of Centella asiatica: modulation of cellular aging. Nutrients 18(11):1649. doi:10.3390/nu18111649. https://doi.org/10.3390/nu18111649
  14. Li Q, Chen W, Xie Y, Zhu H (2026). Therapeutic potential of asiaticoside in wound healing after endoscopic submucosal dissection (ESD). Pharmaceutical Biology 64(1):487–513. doi:10.1080/13880209.2026.2638602. https://doi.org/10.1080/13880209.2026.2638602